The DDIR assay was originally developed in breast cancer and constitutes a 44-gene assay19 indicating constitutive activation of the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway in response to DNA damaging chemotherapy20. The gene discussed is STING1; the disease is breast carcinoma.